Not investment advice. FilingSight is an automated analytical research tool, not a registered investment advisor. Ratings and scores are quantitative analytical classifications, not buy or sell recommendations. Nothing here is personalized to your circumstances. Investing involves risk of loss — consult a licensed professional. See full disclosures.
Colgate-Palmolive
CLConsumer StaplesGenerated Aug 21, 2026, 12:13 AM UTC
CL (Colgate-Palmolive) analytical snapshot. Revenue grew +1.4% YoY to $20.38B. 5-year revenue CAGR +3.2%; 10y CAGR +3.3%. Net margin at 10.46% (expanding ▲). Market cap $71.51B at $89.70 per share. Trailing P/E 34.11, P/S 3.51, P/B 302.99. EV/Operating income ≈ 23.59 (EV $77.98B). Risk: Elevated. Macro: Risk-on · Supportive. Composite analytical score -3 (data confidence 84%). Descriptive analytics from public filings — not investment advice.
Free SEC analysis
— computed from SEC filings, free to readFilings & Ownership
Latest annual report (10-K) filed Feb 23, 2026. Latest quarterly report (10-Q) filed Jul 31, 2026. 12 recent 8-K material-event filings in the index.
- Latest annual report (10-K) filed Feb 23, 2026.
- Latest quarterly report (10-Q) filed Jul 31, 2026.
- 12 recent 8-K material-event filings in the index.
- Recent insider Form 4s: 0 buy vs 0 sell transactions.
| Date | Form | Description |
|---|---|---|
| Jul 31, 2026 | 8-K | 8-K |
| May 13, 2026 | 8-K | 8-K |
| May 1, 2026 | 8-K | 8-K |
| Apr 9, 2026 | 8-K | 8-K |
| Mar 17, 2026 | 8-K | 8-K |
| Mar 12, 2026 | 8-K | 8-K |
| Jan 30, 2026 | 8-K | 8-K |
| Nov 10, 2025 | 8-K | FORM 8-K |
SEC Filing Deep-Analysis
1 positive signal(s) detected from XBRL filing diff analysis. 1 positive signal(s) versus 0 risk signal(s). The filing exhibits more constructive indicators than concerns, though individual risk factors should still be monitored.
- Operating cash flow exceeds net income: OCF is 1.97x net income, indicating high earnings quality — cash conversion is strong and accruals are not inflating reported profits.
- Endogenous analysis: 1 positive signal(s) versus 0 risk signal(s). The filing exhibits more constructive indicators than concerns, though individual risk factors should still be monitored.
- 1 new XBRL disclosure(s) in latest filing — expanding reporting scope.
- 20 disclosure(s) dropped from prior year — reduced reporting granularity.
| Metric | Prior year | Latest year | Change | % Change |
|---|---|---|---|---|
| Revenue | $20.10B | $20.38B | $281.0M | +1.4% |
| Gross profit | $12.16B | $12.25B | $90.0M | +0.7% |
| Operating income | $4.27B | $3.31B | $-962.0M | -22.5% |
| Net income | $2.89B | $2.13B | $-757.0M | -26.2% |
| Operating cash flow | $4.11B | $4.20B | $91.0M | +2.2% |
| Capex | $561.0M | $564.0M | $3.0M | +0.5% |
| Total assets | $16.05B | $16.33B | $284.0M | +1.8% |
| Total liabilities | $15.50B | $15.96B | $463.0M | +3.0% |
| Long-term debt | $7.00B | $7.84B | $834.0M | +11.9% |
| Cash & equivalents | $1.10B | $1.29B | $192.0M | +17.5% |
| Stockholders equity | $212.0M | $54.0M | $-158.0M | -74.5% |
| Inventory | $1.99B | $2.03B | $45.0M | +2.3% |
| Accounts receivable | $1.52B | $1.68B | $154.0M | +10.1% |
| R&D expense | $355.0M | $366.0M | $11.0M | +3.1% |
| SG&A expense | $7.73B | $7.90B | $174.0M | +2.3% |
| Interest expense | $172.0M | $299.0M | $127.0M | +73.8% |
| Type | Concepts |
|---|---|
| Added | SupplierFinanceProgramObligation |
| Removed | AccrualForTaxesOtherThanIncomeTaxesCurrent, AdvertisingExpense, AllocatedShareBasedCompensationExpense, AmortizationOfIntangibleAssets, BuildingsAndImprovementsGross, CommitmentsAndContingencies, CommonStockSharesOutstanding, DeferredIncomeTaxExpenseBenefit, DeferredIncomeTaxLiabilities, DeferredOtherTaxExpenseBenefit |
Fundamentals
Revenue grew +1.4% YoY to $20.38B. 5-year revenue CAGR +3.2%; 10y CAGR +3.3%. Net margin at 10.46% (expanding ▲).
- Revenue grew +1.4% YoY to $20.38B.
- 5-year revenue CAGR +3.2%; 10y CAGR +3.3%.
- Net margin at 10.46% (expanding ▲).
- Return on equity 3948.15%, ROA 13.06%, ROIC 41.89%.
- Gross margin 60.11%, operating margin 16.22%.
- Free cash flow margin 17.83% ($3.63B).
- Net income down ▼ +26.2% YoY.
- Debt/equity 33.22, current ratio 1.03, net debt $6.47B.
- Asset turnover 1.21 — capital efficiency.
| FY | Revenue | Rev YoY | Gross% | Op% | Net% | FCF | ROE% |
|---|---|---|---|---|---|---|---|
| 2024 | $20.10B | +3.3% | 60.50 | 21.23 | 14.37 | $3.55B | 1362.74 |
| 2025 | $20.38B | +1.4% | 60.11 | 16.22 | 10.46 | $3.63B | 3948.15 |
| Quarter end | Revenue | YoY | QoQ | Net margin |
|---|---|---|---|---|
| Jun 30, 2016 | $3.85B | -5.4% | — | 15.60% |
| Sep 30, 2016 | $3.87B | -3.3% | +0.6% | 18.15% |
| Mar 31, 2017 | $3.76B | 0.0% | -2.7% | 15.15% |
| Jun 30, 2017 | $3.83B | -0.5% | +1.7% | 13.70% |
| Sep 30, 2017 | $3.97B | +2.8% | +3.9% | 15.27% |
| Mar 31, 2018 | $4.00B | +6.4% | +0.7% | 15.84% |
Pro analysis — preview
— score, signals & key metrics shown; full reasoning lockedValuation
Market cap $71.51B at $89.70 per share. Trailing P/E 34.11, P/S 3.51, P/B 302.99. EV/Operating income ≈ 23.59 (EV $77.98B).
- Market cap $71.51B at $89.70 per share.
Price & Technicals
Price $89.70 — uptrend (above 200-DMA); 1-month momentum negative. RSI(14) 43.69.
- Price $89.70 — uptrend (above 200-DMA); 1-month momentum negative.
Macro & Rates
Risk-on · Supportive. Real GDP growth 1.50% (quarterly, as of Apr 1, 2026). CPI inflation +3.3% YoY. Fed funds rate 3.63%, 10Y Treasury 4.65%.
- Market regime: Risk-on · Supportive.
Risk Scorecard
Composite risk Elevated. Leverage debt/equity 33.22 (high). Liquidity current ratio 1.03 (adequate).
- Composite risk: Elevated.
See the full picture behind every stock
Unlock the complete 10-year fundamentals, DCF & Graham intrinsic value, 13F/13D ownership flow, risk scorecard, multi-analyst bull/bear debate — plus watchlist alerts and your research workspace. Start with a 14-day Pro trial.
3 sections free · 4 Pro previews · composite -3
Macro exposure
Defensive · Low sensitivityMacro regime: Risk-on · Supportive. Colgate-Palmolive is a defensive name (low macro sensitivity) — a supportive backdrop, though defensives lag risk-on tapes.
Analytical read
deterministic previewMarket regime: Risk-on · Supportive..
Peer comparison
Defensive groupHow CL stacks up against tracked peers with similar macro sensitivity — by analytical score and macro exposure.
| Company | Score | Macro |
|---|---|---|
| DexCom Inc. DXCM | 19 | Neutral |
| Bristol-Myers Squibb BMY | 19 | Neutral |
| Eli Lilly & Co. LLY | 17 | Neutral |
| Gilead Sciences GILD | 9 | Neutral |
| Regeneron Pharmaceuticals REGN | 9 | Neutral |
| HCA Healthcare HCA | 9 | Neutral |
| Johnson & Johnson JNJ | 8 | Neutral |
| Abbott Laboratories ABT | 7 | Neutral |
| Intuitive Surgical Inc. ISRG | 7 | Neutral |
| Zoetis Inc. ZTS | 6 | Neutral |
| Coca-Cola Co. KO | 6 | Neutral |
| Biogen Inc. BIIB | 6 | Neutral |
| Vertex Pharmaceuticals VRTX | 5 | Neutral |
| Thermo Fisher Scientific TMO | 3 | Neutral |
| Danaher Corp. DHR | 1 | Neutral |
| Merck & Co. MRK | 0 | Neutral |
| Illumina Inc. ILMN | 0 | Neutral |
| Colgate-Palmolive CL● you | -3 | Neutral |
| AbbVie Inc. ABBV | -8 | Neutral |
| CVS Health Corp. CVS | -8 | Neutral |
| Walmart Inc. WMT | -8 | Neutral |
| Cigna Group CI | -9 | Neutral |
| Amgen Inc. AMGN | -9 | Neutral |
| Procter & Gamble PG | -10 | Neutral |
| Mondelez International MDLZ | -10 | Neutral |
| Pfizer Inc. PFE | -13 | Neutral |
| Kroger Co. KR | -15 | Neutral |
| PepsiCo Inc. PEP | -16 | Neutral |
| Sysco Corp. SYY | -16 | Neutral |
| Hershey Co. HSY | -17 | Neutral |
| Kimberly-Clark Corp. KMB | -18 | Neutral |
| Costco Wholesale COST | -18 | Neutral |
| Moderna Inc. MRNA | -21 | Neutral |
| UnitedHealth Group UNH | -25 | Neutral |